1-12 of 12
myeloma cells
Close
Sort by
Journal Articles

IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms

Liang Zhou, Yu Zhang, Mark B. Meads, Yun Dai, Yanxia Ning, Xiaoyan Hu, Lin Li, Kanika Sharma, Jewel Nkwocha, Rebecca Parker, Danny Bui, Jacquelyn McCarter, Lora Kramer, Cullen Purcell, Praneeth R. Sudalagunta, Rafael R. Canevarolo, Maria D. Coelho Siqueira Silva, Gabriel De Avila, Raghunandan Reddy Alugubelli, Ariosto S. Silva, Maciej Kmeiciak, Andrea Ferreira-Gonzalez, Kenneth H. Shain, Steven Grant
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3776–3788.
https://doi.org/10.1182/bloodadvances.2020003597
Published: 2021
Includes: Supplemental data
Journal Articles

DKK1 activates noncanonical NF-κB signaling via IL-6–induced CKAP4 receptor in multiple myeloma

Xin Li, Jingjing Wang, Shuai Zhu, Jinxin Zheng, Ying Xie, Hongmei Jiang, Jing Guo, Yixuan Wang, Ziyi Peng, Mengqi Wang, Jingya Wang, Sheng Wang, Yuping Zhong, Zhiqiang Liu
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3656–3667.
https://doi.org/10.1182/bloodadvances.2021004315
Published: 2021
Includes: Supplemental data
Journal Articles

CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma

Poornima Ramkumar, Anthony B. Abarientos, Ruilin Tian, Meghan Seyler, Jaime T. Leong, Merissa Chen, Priya Choudhry, Torsten Hechler, Nina Shah, Sandy W. Wong, Thomas G. Martin, III, Jeffrey L. Wolf, Kole T. Roybal, Andreas Pahl, Jack Taunton, Arun P. Wiita, Martin Kampmann
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2899–2911.
https://doi.org/10.1182/bloodadvances.2019001346
Published: 2020
Includes: Supplemental data
Journal Articles

CD4 + T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages

Ole Audun W. Haabeth, Kjartan Hennig, Marte Fauskanger, Geir Åge Løset, Bjarne Bogen, Anders Tveita
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2595–2605.
https://doi.org/10.1182/bloodadvances.2020001434
Published: 2020
Includes: Supplemental data
Journal Articles

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma

Andrea Schmidts, Maria Ormhøj, Bryan D. Choi, Allison O. Taylor, Amanda A. Bouffard, Irene Scarfò, Rebecca C. Larson, Matthew J. Frigault, Kathleen Gallagher, Ana P. Castano, Lauren S. Riley, Maria L. Cabral, Angela C. Boroughs, Rubí M.-H. Velasco Cárdenas, Wolfgang Schamel, Jing Zhou, Sean Mackay, Yu-Tzu Tai, Kenneth C. Anderson, Marcela V. Maus
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3248–3260.
https://doi.org/10.1182/bloodadvances.2019000703
Published: 2019
Includes: Supplemental data
Journal Articles

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

Ralf Buettner, Corey Morales, Enrico Caserta, Estelle Troadec, Emine G. Gunes, Domenico Viola, Jihane Khalife, Hongzhi Li, Jonathan J. Keats, Austin Christofferson, Xiwei Wu, Timothy W. Synold, Joycelynne Palmer, James F. Sanchez, Alexander Pozhitkov, Nagarajan Vaidehi, Guido Marcucci, Amrita Krishnan, Michael A. Rosenzweig, Flavia Pichiorri, Steven T. Rosen
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1027–1032.
https://doi.org/10.1182/bloodadvances.2018027227
Published: 2019
Includes: Supplemental data
Journal Articles

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

Chandini M. Thirukkumaran, Zhong Qiao Shi, Gerard J. Nuovo, Joanne Luider, Karen A. Kopciuk, Yuan Dong, Ahmed A. Mostafa, Satbir Thakur, Kathy Gratton, Ailian Yang, Alex C. Chin, Matt C. Coffey, Victor H. Jimenez-Zepeda, Douglas Stewart, Marta Chesi, P. Leif Bergsagel, Don Morris
Journal: Blood Advances
Blood Adv (2019) 3 (5): 797–812.
https://doi.org/10.1182/bloodadvances.2018025593
Published: 2019
Includes: Supplemental data
Journal Articles

p53 regulates CD46 expression and measles virus infection in myeloma cells

Anne Lok, Geraldine Descamps, Benoit Tessoulin, David Chiron, Marion Eveillard, Catherine Godon, Yannick Le Bris, Astrid Vabret, Celine Bellanger, Laurent Maillet, Sophie Barillé-Nion, Marc Gregoire, Jean-François Fonteneau, Steven Le Gouill, Philippe Moreau, Frederic Tangy, Martine Amiot, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck
Journal: Blood Advances
Blood Adv (2018) 2 (23): 3492–3505.
https://doi.org/10.1182/bloodadvances.2018025106
Published: 2018
Includes: Supplemental data
Journal Articles

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

Sondra Downey-Kopyscinski, Ellen W. Daily, Marc Gautier, Ananta Bhatt, Bogdan I. Florea, Constantine S. Mitsiades, Paul G. Richardson, Christoph Driessen, Herman S. Overkleeft, Alexei F. Kisselev
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2443–2451.
https://doi.org/10.1182/bloodadvances.2018016360
Published: 2018
Includes: Supplemental data
Journal Articles

Hypoxia-inducible KDM3A addiction in multiple myeloma

Sho Ikeda, Akihiro Kitadate, Fumito Abe, Naoto Takahashi, Hiroyuki Tagawa
Journal: Blood Advances
Blood Adv (2018) 2 (4): 323–334.
https://doi.org/10.1182/bloodadvances.2017008847
Published: 2018
Includes: Supplemental data
Journal Articles

Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss

Muhammad Zahoor, Marita Westhrin, Kristin Roseth Aass, Siv Helen Moen, Kristine Misund, Katarzyna Maria Psonka-Antonczyk, Mariaserena Giliberto, Glenn Buene, Anders Sundan, Anders Waage, Anne-Marit Sponaas, Therese Standal
Journal: Blood Advances
Blood Adv (2017) 1 (27): 2656–2666.
https://doi.org/10.1182/bloodadvances.2017010801
Published: 2017
Includes: Supplemental data
Journal Articles

CD86 regulates myeloma cell survival

Catherine M. Gavile, Benjamin G. Barwick, Scott Newman, Paola Neri, Ajay K. Nooka, Sagar Lonial, Kelvin P. Lee, Lawrence H. Boise
Journal: Blood Advances
Blood Adv (2017) 1 (25): 2307–2319.
https://doi.org/10.1182/bloodadvances.2017011601
Published: 2017
Includes: Supplemental data